Determination of CH330331, a novel 4-anilinoquinazoline inhibitor of epidermal growth factor receptor tyrosine kinase, in human Caco-2 monolayers by high performance liquid chromatography with ultraviolet detection: Application to a trans-epithelial transport study

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 854, Issue 1-2, 2007, Pages 320-327

  Sun, Hai Yan ^a,b   Guan, Su ^a   Bi, Hui Chang ^a   Su, Qi Biao ^a   Huang, Wen Lin ^c   Chowbay, Balram ^d   Huang, Min ^a   Chen, Xiao ^a   Li, Chun Guang ^e   Zhou, Shu Feng ^f  

^a SUN YAT SEN UNIVERSITY   (China)

^b SHENZHEN POLYTECHNIC   (China)

^c SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^d DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^e RMIT UNIVERSITY   (Australia)

^f QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

Caco 2 cells; CH330331; HPLC; Validation

Indexed keywords

CACO-2 CELLS; EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE (EGFR-TK);

ENZYME INHIBITION; GROWTH KINETICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MAMMALS; MONOLAYERS; ONCOLOGY; TOXICITY;

DRUG PRODUCTS;

CH 330331; QUINAZOLINE DERIVATIVE; UNCLASSIFIED DRUG; VERAPAMIL; VERLUKAST;

ARTICLE; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG DETERMINATION; DRUG TRANSPORT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; ULTRAVIOLET RADIATION;

BIOLOGICAL TRANSPORT; CACO-2 CELLS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; EPITHELIUM; HUMANS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; REPRODUCIBILITY OF RESULTS; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 34250706777     PISSN: 15700232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchromb.2007.03.052     Document Type: Article

References (32)

1. Fabbro D., Ruetz S., Buchdunger E., Cowan-Jacob S.W., Fendrich G., Liebetanz J., Mestan J., O'Reilly T., Traxler P., Chaudhuri B., Fretz H., Zimmermann J., Meyer T., Caravatti G., Furet P., and Manley P.W. Pharmacol. Ther. 93 (2002) 79
2. Ono M., and Kuwano M. Clin. Cancer Res. 12 (2006) 7242
3. Schlessinger J., and Lemmon M.A. Cell 127 (2006) 45
4. de Jonge M.J., and Verweij J. Eur. J. Cancer 42 (2006) 1351
5. Levitzki A., and Gazit A. Science 267 (1995) 1782
6. Scaltriti M., and Baselga J. Clin. Cancer Res. 12 (2006) 5268
7. Baselga J. Science 312 (2006) 1175
8. Denny W.A., Rewcastle G.W., Bridges A.J., Fry D.W., and Kraker A.J. Clin. Exp. Pharmacol. Physiol. 23 (1996) 424
9. Shewchuk L., Hassell A., Wisely B., Rocque W., Holmes W., Veal J., and Kuyper L.F. J. Med. Chem. 43 (2000) 133
10. Smaill J.B., Showalter H.D., Zhou H., Bridges A.J., McNamara D.J., Fry D.W., Nelson J.M., Sherwood V., Vincent P.W., Roberts B.J., Elliott W.L., and Denny W.A. J. Med. Chem. 44 (2001) 429
11. Telliez A., Desroses M., Pommery N., Briand O., Farce A., Laconde G., Lemoine A., Depreux P., and Henichart J.P. Chem. Med. Chem. (2007)
12. Hennequin L.F., Ballard P., Boyle F.T., Delouvrie B., Ellston R.P., Halsall C.T., Harris C.S., Hudson K., Kendrew J., Pease J.E., Ross H.S., Smith P., and Vincent J.L. Bioorg. Med. Chem. Lett. 16 (2006) 2672
13. Wang Y.D., Miller K., Boschelli D.H., Ye F., Wu B., Floyd M.B., Powell D.W., Wissner A., Weber J.M., and Boschelli F. Bioorg. Med. Chem. Lett. 10 (2000) 2477
14. Sordella R., Bell D.W., Haber D.A., and Settleman J. Science 305 (2004) 1163
15. Fojo T. Drug Resist. Updat. (2007)
16. Swaisland H.C., Smith R.P., Laight A., Kerr D.J., Ranson M., Wilder-Smith C.H., and Duvauchelle T. Clin. Pharmacokinet. 44 (2005) 1165
17. Swaisland H., Laight A., Stafford L., Jones H., Morris C., Dane A., and Yates R. Clin. Pharmacokinet. 40 (2001) 297
18. Thomas S.M., and Grandis J.R. Cancer Treat. Rev. 30 (2004) 255
19. Ozvegy-Laczka C., Hegedus T., Varady G., Ujhelly O., Schuetz J.D., Varadi A., Keri G., Orfi L., Nemet K., and Sarkadi B. Mol. Pharmacol. 65 (2004) 1485
20. Houghton P.J., Germain G.S., Harwood F.C., Schuetz J.D., Stewart C.F., Buchdunger E., and Traxler P. Cancer Res. 64 (2004) 2333
21. Erlichman C., Boerner S.A., Hallgren C.G., Spieker R., Wang X.Y., James C.D., Scheffer G.L., Maliepaard M., Ross D.D., Bible K.C., and Kaufmann S.H. Cancer Res. 61 (2001) 739
22. Leggas M., Panetta J.C., Zhuang Y., Schuetz J.D., Johnston B., Bai F., Sorrentino B., Zhou S., Houghton P.J., and Stewart C.F. Cancer Res. 66 (2006) 4802
23. Cusatis G., Gregorc V., Li J., Spreafico A., Ingersoll R.G., Verweij J., Ludovini V., Villa E., Hidalgo M., Sparreboom A., and Baker S.D. J. Natl. Cancer Inst. 98 (2006) 1739
24. Li J., Cusatis G., Brahmer J., Sparreboom A., Robey R.W., Bates S.E., Hidalgo M., and Baker S.D. Cancer Biol. Ther. 6 (2007)
25. Gardner E.R., Burger H., van Schaik R.H., van Oosterom A.T., de Bruijn E.A., Guetens G., Prenen H., de Jong F.A., Baker S.D., Bates S.E., Figg W.D., Verweij J., Sparreboom A., and Nooter K. Clin. Pharmacol. Ther. 80 (2006) 192
26. Artursson P., Palm K., and Luthman K. Adv. Drug Deliv. Rev. 46 (2001) 27
27. Artursson P. J. Pharm. Sci. 79 (1990) 476
28. Meunier V., Bourrie M., Berger Y., and Fabre G. Cell Biol. Toxicol. 11 (1995) 187
29. Mosmann T. J. Immunol. Methods 65 (1983) 55
30. Zhou S., Feng X., Kestell P., Paxton J.W., Baguley B.C., and Chan E. Eur. J. Pharm. Sci. 24 (2005) 513
31. Zhou S., Li Y., Kestell P., Schafer P., Chan E., and Paxton J.W. Eur. J. Drug Metab. Pharmacokinet. 30 (2005) 49
32. Karnes H., Shiu G., and Shah V. Pharm. Res. 8 (1991) 421